Update on invasive opportunistic mycoses: Clinical trials review, 2008-2009

Current Infectious Disease Reports

Volumn 11, Issue 6, 2009, Pages 417-419

  Groll, Andreas H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; FLUCONAZOLE; PLACEBO; POSACONAZOLE; VORICONAZOLE;

ACUTE MYELOBLASTIC LEUKEMIA; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; BRAIN DISEASE; CANCER PATIENT; CLINICAL TRIAL; CONCENTRATION RESPONSE; COUGHING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HUMAN; INFECTION PREVENTION; INVASIVE CANDIDIASIS; LUNG ASPERGILLOSIS; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PHLEBITIS; SHORT SURVEY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 70449484479     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0060-0     Document Type: Short Survey

References (10)

1. R.F. Betts M. Nucci D. Talwar Caspofungin High-Dose Study Group, et al. 2009 A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis Clin Infect Dis 48 1676 1684 10.1086/598933 1:CAS:528:DC%2BD1MXot12rtrg%3D 19419331
2. A.H. Groll D. Mickiene R. Petraitiene, et al. 2001 Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling Antimicrob Agents Chemother 45 2845 2855 10.1128/AAC.45.10.2845- 2855.2001 1:CAS:528:DC%2BD3MXntFCisb0%3D 11557479 (Pubitemid 32906681)
3. J. Maertens I. Raad G. Petrikkos Caspofungin Salvage Aspergillosis Study Group, et al. 2004 Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis 39 1563 1571 10.1086/423381 1:CAS:528: DC%2BD2cXhtFGgtr3I 15578352 (Pubitemid 39578526)
4. Herbrecht R, Maertens J, Baila L, et al.: Caspofungin as first-line therapy of invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients: a study of the EORTC Infectious Diseases Group [abstract M2167]. Presented at the American Society for Microbiology 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 25-27, 2008.
5. A.J. Labelle S.T. Micek N. Roubinian M.H. Kollef 2008 Treatment-related risk factors for hospital mortality in Candida bloodstream infections Crit Care Med 36 2967 2972 10.1097/CCM.0b013e31818b3477 18824910
6. M.G. Schuster J.E. Edwards Jr J.D. Sobel, et al. 2008 Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial Ann Intern Med 149 83 90 18626047
7. O.A. Cornely J. Maertens D.J. Winston, et al. 2007 Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 348 359 10.1056/NEJMoa061094 1:CAS:528:DC%2BD2sXhtVGrsrw%3D 17251531 (Pubitemid 46148777)
8. A.J. Ullmann J.H. Lipton D.H. Vesole, et al. 2007 Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease N Engl J Med 356 335 347 10.1056/NEJMoa061098 1:CAS:528:DC%2BD2sXhtVGktb4%3D 17251530 (Pubitemid 46148776)
9. B.J. Rijnders J.J. Cornelissen L. Slobbe, et al. 2008 Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial Clin Infect Dis 46 1401 1408 10.1086/586739 1:CAS:528:DC%2BD1cXlvVGgsLY%3D 18419443 (Pubitemid 351589940)
10. A. Pascual T. Calandra S. Bolay, et al. 2008 Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes Clin Infect Dis 46 201 211 10.1086/524669 1:CAS:528: DC%2BD1cXhvVClsbY%3D 18171251 (Pubitemid 351269158)